Qiao Huai, Yan-Chao Yang, Shu-Zhen Cui, Chen-Xia Jiang, Bu-Lang Gao
Shijiazhuang People’s Hospital, 365 Jian-Hua Street, Shijiazhuang, Hebei Province, China 050030
Introduction: The role of dexmedetomidine in recovery of patients undergoing radical colon cancer resection is unknown, and this study served to investigate its role and mechanism.
Materials and methods: This randomized, controlled, blinded, prospective study enrolled 80 patients undergoing laparoscopic radical resection of colon cancer into two groups: dexmedetomidine (n=40) and control (n=40). Dexmedetomidine was given 0.5 ug.kg-1 for ten minutes and maintained at 0.4 ug.kg-1 per hour. Serum TGF-β, ICAM-1, TNF-α, IL-6, and C-reactive protein were analyzed after anesthesia as the primary outcome and the role in promoting patient recovery as the secondary outcome.
Results: Compared with the control group, the dexmedetomidine group had greater TGF-β (1757.05±139.75 vs. 1566.14±141.32 pg/ml, P<0.05) but lower ICAM-1 (322.47±39.12 vs. 405.15±49.71 ng/ml, P<0.05), IL-6 (123.50±10.34 vs. 150.30±12.69 pg/mL), and TNF-α (43.87±4.61 vs. 58.93±5.46 pg/mL). The dexmedetomidine group had decreased C-reactive protein on the first day after operation (36.65±8.05 vs. 54.70±7.21mg/l, P<0.05), reduced 24-h drainage volume (97.25±23.67 vs. 198.25±36.03 ml, P<0.05), shortened time to get out of bed (23.60±3.21 vs. 34.17±3.84h, P<0.05), quicker recovery of bowel sounds (61.30±6.04 vs. 85.35±8.38 h, P<0.05), quicker anal exhaust (65.15±6.10 vs. 89.48±8.32 h, P<0.05) and shortened hospital stay (6.58±0.65 vs. 7.85±0.86 d, P<0.05). The ROC curve analysis revealed a high area under the curve > 0.9 for all these parameters.
Conclusion: Dexmedetomidine can promote the healing of surgical wound and reduce the occurrence of postoperative adhesion by regulating the expression of cytokines, which is conducive to the rapid recovery of patients with colon cancer.
Dexmedetomidine, Colon cancer, Cytokine, Laparoscopy.
10.19193/0393-6384_2022_1_48